I couldn't resist. I had to respond to Plotinus.
Plotinus, you’ve captured the Information Asymmetry which defines this stage of the lifecycle perfectly. While some wait for the "8-week scan" like it’s a standard high school report card, the Apex Predators (Big Pharma) are already sitting in the Virtual Data Room looking at the raw biological feed.
Your point about the "Cold-to-Hot" themed congress (AACR) is the "Tell." You don't get an abstract accepted at a major oncology congress based on a "hunch", you get it based on Preliminary Bio-Inference, let along one to be presented by a member of the International Scientific Advisory Board discussing a proven topic he formed his Stroma Genesis Company upon.
The Dual-Track Data Feed
You’ve identified two distinct audiences for the MSS-CRC data:
1. The Public Tape (Shareholders): The PRs and shareholder letters are the Teasers. They provide enough to keep the lights on and the $0.2450 Weld intact. To the retail eye, this looks like a slow crawl.
2. The War Room (NDA/Big Pharma): As you note, this is likely happening now. In the Makary-Prasad Paradigm, the most valuable data isn't the final survival curve 8 years down the road; it’s the Early Signal of Unmasking.
The Early Observation: If the first 5-10 patients showed immediate PD-L1 upregulation (The Unmasking) and a drop in ctDNA (The Body Count), that is all a scout for Merck, Roche, GSK or even Gilead needs to see to begin the Buyout Math. They don't need a 12-week scan to know the M1/M2 Macrophage Inversion has occurred, the biology tells the story in the first 28 days.
The Binary Event vs. The Regulatory Moat Dr. Jay Lalezari’s admission that CytoDyn is unlikely to commercialize is the ultimate De-risking Statement. It tells the market that this is a Turnkey Utility.
The Math of the Re-set: If a partnership or buyout is the Binary Event, the protracted FDA timelines become Operational Noise. The acquirer isn't buying a company that has to build a sales force; they are buying a Biological Primer in order to save their own expiring patents.
The Buyout Premium (P_b): In this scenario, the valuation isn't based on CytoDyn’s current cash flow (which is "sketchy," as ScoreCarder noted), but rather on the NPV of the Patent Extension (E_p) for the buyer.
P_b = Current Market Cap + Strategic Value of E_p
Plotinus, your read on the Binary Event aligns with my read. The share price is currently anchored by those who see only the protracted timelines. But the price re-set occurs the moment the War Room data moves from an NDA to a Binding Offer.
The "Dementia" some see in this community is actually just Advanced Pattern Recognition. We aren't watching the scans; we are watching the Geography of the Exit.
Let the tape play out.
Plotinus, you’ve captured the Information Asymmetry which defines this stage of the lifecycle perfectly. While some wait for the "8-week scan" like it’s a standard high school report card, the Apex Predators (Big Pharma) are already sitting in the Virtual Data Room looking at the raw biological feed.
Your point about the "Cold-to-Hot" themed congress (AACR) is the "Tell." You don't get an abstract accepted at a major oncology congress based on a "hunch", you get it based on Preliminary Bio-Inference, let along one to be presented by a member of the International Scientific Advisory Board discussing a proven topic he formed his Stroma Genesis Company upon.
The Dual-Track Data Feed
You’ve identified two distinct audiences for the MSS-CRC data:
1. The Public Tape (Shareholders): The PRs and shareholder letters are the Teasers. They provide enough to keep the lights on and the $0.2450 Weld intact. To the retail eye, this looks like a slow crawl.
2. The War Room (NDA/Big Pharma): As you note, this is likely happening now. In the Makary-Prasad Paradigm, the most valuable data isn't the final survival curve 8 years down the road; it’s the Early Signal of Unmasking.
The Early Observation: If the first 5-10 patients showed immediate PD-L1 upregulation (The Unmasking) and a drop in ctDNA (The Body Count), that is all a scout for Merck, Roche, GSK or even Gilead needs to see to begin the Buyout Math. They don't need a 12-week scan to know the M1/M2 Macrophage Inversion has occurred, the biology tells the story in the first 28 days.
The Binary Event vs. The Regulatory Moat Dr. Jay Lalezari’s admission that CytoDyn is unlikely to commercialize is the ultimate De-risking Statement. It tells the market that this is a Turnkey Utility.
The Math of the Re-set: If a partnership or buyout is the Binary Event, the protracted FDA timelines become Operational Noise. The acquirer isn't buying a company that has to build a sales force; they are buying a Biological Primer in order to save their own expiring patents.
The Buyout Premium (P_b): In this scenario, the valuation isn't based on CytoDyn’s current cash flow (which is "sketchy," as ScoreCarder noted), but rather on the NPV of the Patent Extension (E_p) for the buyer.
P_b = Current Market Cap + Strategic Value of E_p
Plotinus, your read on the Binary Event aligns with my read. The share price is currently anchored by those who see only the protracted timelines. But the price re-set occurs the moment the War Room data moves from an NDA to a Binding Offer.
The "Dementia" some see in this community is actually just Advanced Pattern Recognition. We aren't watching the scans; we are watching the Geography of the Exit.
Let the tape play out.
15
